Skip to main content
Premium Trial:

Request an Annual Quote

Clock Soon to Start Ticking on Myriad s 3-Year Proteome Effort

SAN FRANCISCO, Jan. 9 - Myriad Proteomics in mid-January will begin trying to fulfill its pledge to map the human proteome within three years as researchers get set to move into the company's new facility, Peter Meldrum, CEO of Myriad Genetics, said on Wednesday.


Move-in day, Jan. 16, is when the three-year time clock starts ticking.


In April, Myriad joined with Hitachi and Oracle to start Myriad Proteomics. Since that time, Myriad Proteomics has designed, built, and furnished its facility Salt Lake City and hired a 50-person staff, Meldrum said. He spoke at the 20th annual JPMorgan H&Q Healthcare Conference here, which ends on Thursday.


Myriad Genetics has 50 percent ownership in the proteomics venture. "They will map the human proteome and we will get free access to the data," said Meldrum.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.